What is the mechanism of XWL-1-48's potent antitumor activity in human hepatocellular carcinoma, and how does it involve inhibiting topoisomerase II, enhancing Mdm2 degradation, inducing DNA damage, inactivating the Cyclin A/Cdk2 complex, activating apoptotic pathways, and inhibiting HCC cell survival?